Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. / Juncker-Jensen, A.; Lykkesfeldt, A. E.; Worm, J.; Ralfkiær, U.; Espelund, U.; Jepsen, J. S.

In: Growth Hormone and IGF Research, Vol. 16, No. 4, 01.08.2006, p. 224-239.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Juncker-Jensen, A, Lykkesfeldt, AE, Worm, J, Ralfkiær, U, Espelund, U & Jepsen, JS 2006, 'Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator', Growth Hormone and IGF Research, vol. 16, no. 4, pp. 224-239. https://doi.org/10.1016/j.ghir.2006.06.005

APA

Juncker-Jensen, A., Lykkesfeldt, A. E., Worm, J., Ralfkiær, U., Espelund, U., & Jepsen, J. S. (2006). Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Hormone and IGF Research, 16(4), 224-239. https://doi.org/10.1016/j.ghir.2006.06.005

Vancouver

Juncker-Jensen A, Lykkesfeldt AE, Worm J, Ralfkiær U, Espelund U, Jepsen JS. Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. Growth Hormone and IGF Research. 2006 Aug 1;16(4):224-239. https://doi.org/10.1016/j.ghir.2006.06.005

Author

Juncker-Jensen, A. ; Lykkesfeldt, A. E. ; Worm, J. ; Ralfkiær, U. ; Espelund, U. ; Jepsen, J. S. / Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator. In: Growth Hormone and IGF Research. 2006 ; Vol. 16, No. 4. pp. 224-239.

Bibtex

@article{022a0a7c8b764b57b4d035377f0b0a18,
title = "Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator",
abstract = "Antiestrogens target the estrogen receptor and counteract the growth stimulatory action of estrogen on human breast cancer. However, acquired resistance to antiestrogens is a major clinical problem in endocrine treatment of breast cancer patients. To mimic acquired resistance, we have used a model system with the antiestrogen sensitive human breast cancer cell line MCF-7 and several antiestrogen resistant cell lines derived from the parental MCF-7 cell line. This model system was used to study the expression and possible involvement in resistant cell growth of insulin-like growth factor binding protein 2 (IGFBP-2). By an oligonucleotide based microarray, we compared the expression of mRNAs encoding insulin-like growth factor binding protein 1,2,3,4,5 and 6 (IGFBP-1 to -6) in the parental MCF-7 cell line to three human breast cancer cell lines, resistant to the antiestrogen ICI 182,780 (Faslodex/Fulvestrant). Only IGFBP-2 mRNA was overexpressed in all three resistant cell lines. Thus, we compared the IGFBP-2 protein expression in MCF-7 cells to nine antiestrogen resistant breast cancer cell lines, resistant to either ICI 182,780 or tamoxifen or RU 58,668 and found that IGFBP-2 was overexpressed in all nine resistant cell lines. Three of the resistant cell lines, resistant to different antiestrogens, were selected for further studies and IGFBP-2 overexpression was demonstrated at the mRNA level as well as the intra- and extracellular protein level. The objective of this study was to examine if IGFBP-2 is involved in growth of antiestrogen resistant human breast cancer cells. Therefore, IGFBP-2 expression was inhibited by antisense oligonucletides and siRNA. Specific inhibition of IGFBP-2 protein expression was achieved in MCF-7 and the three selected antiestrogen resistant cell lines, but no effect on resistant cell growth was observed. Thus, we were able to establish IGFBP-2 as a marker for antiestrogen resistant breast cancer cell lines, although IGFBP-2 was not a major contributor to the resistant cell growth.",
keywords = "Antiestrogen resistance, Breast cancer, ICI 182,780 (Faslodex/Fulvestrant), Insulin-like growth factor binding protein 2, MCF-7, RU 58,668, Tamoxifen",
author = "A. Juncker-Jensen and Lykkesfeldt, {A. E.} and J. Worm and U. Ralfki{\ae}r and U. Espelund and Jepsen, {J. S.}",
year = "2006",
month = aug,
day = "1",
doi = "10.1016/j.ghir.2006.06.005",
language = "English",
volume = "16",
pages = "224--239",
journal = "Growth Hormone & I G F Research",
issn = "1096-6374",
publisher = "Churchill Livingstone",
number = "4",

}

RIS

TY - JOUR

T1 - Insulin-like growth factor binding protein 2 is a marker for antiestrogen resistant human breast cancer cell lines but is not a major growth regulator

AU - Juncker-Jensen, A.

AU - Lykkesfeldt, A. E.

AU - Worm, J.

AU - Ralfkiær, U.

AU - Espelund, U.

AU - Jepsen, J. S.

PY - 2006/8/1

Y1 - 2006/8/1

N2 - Antiestrogens target the estrogen receptor and counteract the growth stimulatory action of estrogen on human breast cancer. However, acquired resistance to antiestrogens is a major clinical problem in endocrine treatment of breast cancer patients. To mimic acquired resistance, we have used a model system with the antiestrogen sensitive human breast cancer cell line MCF-7 and several antiestrogen resistant cell lines derived from the parental MCF-7 cell line. This model system was used to study the expression and possible involvement in resistant cell growth of insulin-like growth factor binding protein 2 (IGFBP-2). By an oligonucleotide based microarray, we compared the expression of mRNAs encoding insulin-like growth factor binding protein 1,2,3,4,5 and 6 (IGFBP-1 to -6) in the parental MCF-7 cell line to three human breast cancer cell lines, resistant to the antiestrogen ICI 182,780 (Faslodex/Fulvestrant). Only IGFBP-2 mRNA was overexpressed in all three resistant cell lines. Thus, we compared the IGFBP-2 protein expression in MCF-7 cells to nine antiestrogen resistant breast cancer cell lines, resistant to either ICI 182,780 or tamoxifen or RU 58,668 and found that IGFBP-2 was overexpressed in all nine resistant cell lines. Three of the resistant cell lines, resistant to different antiestrogens, were selected for further studies and IGFBP-2 overexpression was demonstrated at the mRNA level as well as the intra- and extracellular protein level. The objective of this study was to examine if IGFBP-2 is involved in growth of antiestrogen resistant human breast cancer cells. Therefore, IGFBP-2 expression was inhibited by antisense oligonucletides and siRNA. Specific inhibition of IGFBP-2 protein expression was achieved in MCF-7 and the three selected antiestrogen resistant cell lines, but no effect on resistant cell growth was observed. Thus, we were able to establish IGFBP-2 as a marker for antiestrogen resistant breast cancer cell lines, although IGFBP-2 was not a major contributor to the resistant cell growth.

AB - Antiestrogens target the estrogen receptor and counteract the growth stimulatory action of estrogen on human breast cancer. However, acquired resistance to antiestrogens is a major clinical problem in endocrine treatment of breast cancer patients. To mimic acquired resistance, we have used a model system with the antiestrogen sensitive human breast cancer cell line MCF-7 and several antiestrogen resistant cell lines derived from the parental MCF-7 cell line. This model system was used to study the expression and possible involvement in resistant cell growth of insulin-like growth factor binding protein 2 (IGFBP-2). By an oligonucleotide based microarray, we compared the expression of mRNAs encoding insulin-like growth factor binding protein 1,2,3,4,5 and 6 (IGFBP-1 to -6) in the parental MCF-7 cell line to three human breast cancer cell lines, resistant to the antiestrogen ICI 182,780 (Faslodex/Fulvestrant). Only IGFBP-2 mRNA was overexpressed in all three resistant cell lines. Thus, we compared the IGFBP-2 protein expression in MCF-7 cells to nine antiestrogen resistant breast cancer cell lines, resistant to either ICI 182,780 or tamoxifen or RU 58,668 and found that IGFBP-2 was overexpressed in all nine resistant cell lines. Three of the resistant cell lines, resistant to different antiestrogens, were selected for further studies and IGFBP-2 overexpression was demonstrated at the mRNA level as well as the intra- and extracellular protein level. The objective of this study was to examine if IGFBP-2 is involved in growth of antiestrogen resistant human breast cancer cells. Therefore, IGFBP-2 expression was inhibited by antisense oligonucletides and siRNA. Specific inhibition of IGFBP-2 protein expression was achieved in MCF-7 and the three selected antiestrogen resistant cell lines, but no effect on resistant cell growth was observed. Thus, we were able to establish IGFBP-2 as a marker for antiestrogen resistant breast cancer cell lines, although IGFBP-2 was not a major contributor to the resistant cell growth.

KW - Antiestrogen resistance

KW - Breast cancer

KW - ICI 182,780 (Faslodex/Fulvestrant)

KW - Insulin-like growth factor binding protein 2

KW - MCF-7

KW - RU 58,668

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=33748080758&partnerID=8YFLogxK

U2 - 10.1016/j.ghir.2006.06.005

DO - 10.1016/j.ghir.2006.06.005

M3 - Journal article

C2 - 16893667

AN - SCOPUS:33748080758

VL - 16

SP - 224

EP - 239

JO - Growth Hormone & I G F Research

JF - Growth Hormone & I G F Research

SN - 1096-6374

IS - 4

ER -

ID: 221753674